An example of such an approach is the recently published PBPK model for vincristine and its application to predict potential drug–drug interactions with Bruton tyrosine kinase inhibitors being added to R‐CHOP protocols for lymphoma.25 The gene discussed is BTK; the disease is lymphoma.